CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy
Cancer immunotherapy activates the immune system to specifically target malignant cells. Research has often focused on CD8+ cytotoxic T cells, as those have the capacity to eliminate tumor cells after specific recognition upon TCR-MHC class I interaction. However, CD4+ T cells have gained attention...
Main Authors: | Jennifer R. Richardson, Anna Schöllhorn, Cécile Gouttefangeas, Juliane Schuhmacher |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/4/596 |
Similar Items
-
Epigenetic Reprogramming of CD4+ Helper T Cells as a Strategy to Improve Anticancer Immunotherapy
by: Elodie Renaude, et al.
Published: (2021-06-01) -
Editorial: CD4+ T Cells in Cancer Immunotherapies
by: José M. González-Navajas, et al.
Published: (2021-09-01) -
Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer
by: Margaux Saillard, et al.
Published: (2021-05-01) -
CD4<sup>+</sup> T Cells in Chronic Hepatitis B and T Cell-Directed Immunotherapy
by: Sonja I. Buschow, et al.
Published: (2021-05-01) -
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
by: Amrita Basu, et al.
Published: (2021-05-01)